Artikelen

Ovarian cancer.

Information on current developments in both regular and alternative or complementary treatments and resources in ovarian cancer at all stages. We have as good as possible, put everything in alphabetical order, see left column to make it even easier and faster to get information.

Metformin, a widely used medication for diabetes 2 to regulate the blood glucose mirror shows disease-free and overall survival time to greatly improve with time eierstokkankerpatienten. Article update 23 February 2012

This article is a few hours worked. Look up, translate, places etc. If you want to support us you can do so through a donation anonymous or not. Any amount is welcome no matter how small. Click here if you want to help us to keep cancer-news online We are an ANBI organization and so your donation is tax-deductible.

10 January 2012: Obstetrics & Gynecology: January 2012-source: Volume 119-Issue 1-p 61 – 67 doi: 0b013e3182393ab3 10.1097/AOG.

Metformin, a drug that regulates the blood glucose in type 2 diabetes mellitus mirror and widely used (diabetes), allows for double disease free time and significantly better survival rates in patients with ovarian cancer who also have diabetes (type 2 diabetes). Even compared with patients with ovarian cancer that had metformin revealed no sugar disease a longer disease free time and also to achieve a significantly longer survival time. This is evidenced by a retro postpectieve study (study in retrospect) performed at the University of Chicago at total 341 women with stage I to IV ovarian cancer. The researchers conclude that metformin apparently an anti tumor effect.

Metformin (trade name among other Glucophage, Riomet, Fortamet, Glumetza, Obimet, Dianben, Diabex, Diaformin) is a drug from the biguanides group group that is used mainly in the treatment of type 2 diabetes mellitus (diabetes) and prevention of the complications that accompany it. More information about wat metformin is exactly on information in Wikipedia about it, click here.

The results:

The researchers looked at the medical records of 341 women with ovarian cancer, ranging from stage I to IV. Epithelial ovarian cancer, 34 thereof had 273 patients had tumors in the fallopian tubes and 34 patients-peritoneal tumors throughout the abdominal cavity. 44 also alongside their ovarian cancer patients had type 2 diabetes mellitus (diabetes). There had 16 people called metformin used thereof and 28 people don't.  All patients were treated in the period 1992 and 2010
All women were given the same treatment for ovarian cancer patient diabetes, regardless of whether they were or not.  In both groups were proportionally the same number of patients who were first operated on their primary tumor and then a relapse had gotten and divided over both groups had all women on average received a same number of chemotherapy. Almost all women (95%) received chemotherapy based on carboplatin based chemotherapy, usually Platinum and taxol and taxanen.

Noteworthy is that the five year progression free survival a whopping 51% (p = 0.03) was also formerly used in patients with diabetes metformin compared with 8% in patients with diabetes who also had used no metformin. In patients who were alongside their ovarian cancer no diabetes patient showed 23% after 5 years still alive without signs of disease progression.
The overall survival after five years was 63% when metformin users, 23% at non-metformin users and 37% in patients from the non-diabetic Group (p = 0.03).

After checking to standard Clinical pathological parameters, the figures for progression free survival remained for the metformin users statistically significant. For overall survival rates were not statistically significant, the researchers say, but this may have to do with the small according to their number of participating patients. Because in a survival analysis corrected for disturbance factors, in a comparison between eierstokkanker and eierstokkanker patients with diabetes that metformin patients who are not used, used the chance of return of metformin showed the disease dropped considerably in the
metformin users group (hazard ratio 0.38). The patients from the metformin Group also had a lower risk of death during the study (hazard ratio 0.43), although this difference was not statistically significant. The risk of return of the disease or the chance of dying from the disease was also lower in patients with diabetes who previously used metformin compared with the non-diabetic group, but also this decrease was not statistically significant. Eierstokkanker patients with diabetes that had metformin no more chance of a relapse had used (hazard ratio, 1.42) and also more likely to die of their disease (hazard ratio, 1.33) compared with eierstokkanker patients without diabetes.

According to the researchers are their findings in line with other studies that have shown an anti-cancer effects of metformin on several other types of cancer including breast cancer, prostate cancer, colon cancer and ovarian cancer. Other in vitro and in vivo studies have also shown that metformin may improve the response to chemotherapy.
Also in their study showed the best response to chemotherapy in the Group place to have had patients who used eierstokkanker metformin, say the researchers.

Having regard to the retrospective nature of the research results must be regarded as hypothesis-generator and may not be generalized to clinical practice, emphasize the researchers. Despite these restrictions, the researchers say the idea to have that specific anti-diabetes treatments may affect the
survival of patients with both cancer and diabetes. It is also important to note that in many studies has proven to be a safe medication metformin and it is already a widely used and cheap medication, the researchers said.

Here the original abstract of the study. If you click here you can study the full report for a fee .

patients with ovarian cancer and with type II diabetes had longer progression-free survival metformin who used, despite receiving similar treatment for ovarian cancer.